The rapid development of COVID-19 vaccines demonstrated what science can achieve under extraordinary pressure. It also exposed a persistent challenge in vaccine research: comparing immune responses measured by different laboratories using different analytical methods.
As vaccine candidates advanced through clinical trials worldwide, researchers generated vast amounts of immunogenicity data. Yet differences in assay design, target antigens and reporting formats often made direct comparisons difficult. A Personal View article published in The Lancet Microbe examined how the World Health Organization (WHO) International Standard for anti-SARS-CoV-2 immunoglobulin helped address this challenge by creating a common framework for measuring and reporting antibody responses.
The Challenge of Measuring Immunity
Evaluating vaccine-induced immune responses is a cornerstone of vaccine development. Neutralizing antibodies and binding antibodies are frequently used to assess whether a vaccine is generating an immune response associated with protection against disease.
During the early stages of the COVID-19 pandemic, however, laboratories used a wide range of neutralization assays and serological methods. Researchers often reported results using laboratory-specific units, making it difficult to compare findings across studies. A vaccine candidate that appeared to generate strong antibody responses in one trial could not always be directly compared with a candidate evaluated elsewhere.
This lack of harmonization complicated efforts to identify correlates of protection, immune markers that predict whether a person is likely to be protected from infection or disease. Establishing such correlates requires combining and comparing data across multiple studies, populations and vaccine platforms.
Creating a Global Reference Standard
To improve comparability, the WHO Expert Committee on Biological Standardization established the first WHO International Standard for anti-SARS-CoV-2 immunoglobulin in December 2020.
The standard was developed through an international collaborative effort involving 44 laboratories across 15 countries. Researchers evaluated the candidate reference material using 125 different assay methods, including virus neutralization assays and binding antibody tests.
The goal was straightforward: to provide laboratories with a common reference point for calibrating assays and expressing results in standardized units. The findings showed that calibration against the International Standard reduced variability between laboratories and improved agreement among different testing methods. Results that previously appeared difficult to reconcile became more comparable when reported relative to the same reference material.
This harmonization allowed researchers to interpret vaccine immunogenicity data with greater confidence and improved the ability to compare responses across clinical studies.
Supporting Clinical Development and Regulatory Decision-Making
The value of standardized measurements extends well beyond data reporting. As vaccine development evolves, immunogenicity data increasingly support regulatory decisions, particularly when placebo-controlled efficacy trials are no longer practical or ethical. Standardized antibody measurements can help researchers establish immune response thresholds associated with protection, and they support approaches that compare new vaccines with authorized products.
The approach also creates opportunities to pool data across studies, strengthening efforts to define correlates of protection and evaluate vaccine performance in different populations.
Building a Common Framework for Future Vaccines
The lessons learned from COVID-19 extend far beyond a single virus. Future emerging infectious diseases will likely require rapid vaccine development across multiple platforms and geographic regions. Standardized reference materials can help ensure that immune-response data generated in different laboratories remain comparable and interpretable.
The authors advised that “all vaccine developers should report antibody results from clinical trials relative to the WHO International Standard” and concluded that “the comparability of results from different immunogenicity studies has long been considered an optional extra. Any risk–benefit assessment of the appropriate use of the WHO International Standard would confirm the need for a common language for communicating the message regarding the clinical performance of COVID-19 vaccines.”
For clinical researchers, regulators and vaccine developers, the message is clear: generating high-quality data is only part of the challenge. That data must also be interpretable across studies and settings. Common standards provide the foundation for that shared understanding.
As vaccine science continues to advance, the ability to speak the same scientific language may prove essential for translating immunogenicity data into clinical insight, regulatory confidence and more effective responses to future public health threats.
Did you enjoy this blog post? Check out our other blog posts as well as related topics on our Webinar page.
QPS is a global, full-service, GLP/GCP-compliant contract research organization (CRO) delivering the highest grade of discovery, bioanalysis, preclinical and clinical drug development services. Since 1995, QPS has grown from a small bioanalysis shop into a full-service CRO with 1,200+ employees in the US, Europe, Asia and India. Today, QPS offers expanded pharmaceutical contract R&D services with special expertise in pharmacology, DMPK, toxicology, bioanalysis, translational medicine, PBMC processing, central safety labs, clinical trials, and clinical research services. An award-winning leader focused on bioanalysis and clinical trials, QPS is known for proven quality standards, technical expertise, a flexible approach to research, client satisfaction, turnkey laboratories, Phase I/II clinical units, and multi-site clinical research services. Through continual enhancements in capacities and resources, QPS stands tall in its commitment to delivering superior quality, skilled performance, and trusted service to its valued customers. For more information, visit www.qps.com or email info@qps.com.